TR199902033T2 - Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari. - Google Patents

Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari.

Info

Publication number
TR199902033T2
TR199902033T2 TR1999/02033T TR9902033T TR199902033T2 TR 199902033 T2 TR199902033 T2 TR 199902033T2 TR 1999/02033 T TR1999/02033 T TR 1999/02033T TR 9902033 T TR9902033 T TR 9902033T TR 199902033 T2 TR199902033 T2 TR 199902033T2
Authority
TR
Turkey
Prior art keywords
glitazone
diabetes
sulfonylura
synergistic combinations
antidiabetic agent
Prior art date
Application number
TR1999/02033T
Other languages
English (en)
Inventor
W. Whitcomb Randall
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR199902033T2 publication Critical patent/TR199902033T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus, diyabetin tedaviye ihtiyaç duyan hastaya bir sülfonilurea antidiyabetik madde ile bir glitazon antidiyabetik maddenin bir kombinasyonunun verilmesiyle tedavisi için bir yöntem saglanmaktadir.
TR1999/02033T 1997-02-19 1997-12-01 Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari. TR199902033T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19

Publications (1)

Publication Number Publication Date
TR199902033T2 true TR199902033T2 (tr) 2000-02-21

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02033T TR199902033T2 (tr) 1997-02-19 1997-12-01 Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari.

Country Status (29)

Country Link
US (2) US5859037A (tr)
EP (1) EP0957923A1 (tr)
JP (1) JP2001512478A (tr)
KR (1) KR20000071179A (tr)
CN (1) CN1244801A (tr)
AR (1) AR011829A1 (tr)
AU (1) AU741215B2 (tr)
BG (1) BG103671A (tr)
BR (1) BR9714505A (tr)
CA (1) CA2272478A1 (tr)
CZ (1) CZ289299A3 (tr)
EA (1) EA199900725A1 (tr)
EE (1) EE9900345A (tr)
GT (1) GT199800037A (tr)
HN (1) HN1997000167A (tr)
HU (1) HUP0001528A3 (tr)
IL (1) IL130027A (tr)
IS (1) IS5058A (tr)
NO (1) NO993982L (tr)
NZ (1) NZ336002A (tr)
PA (1) PA8447401A1 (tr)
PE (1) PE74399A1 (tr)
PL (1) PL335166A1 (tr)
SK (1) SK111899A3 (tr)
SV (1) SV1998000010A (tr)
TR (1) TR199902033T2 (tr)
UY (1) UY24893A1 (tr)
WO (1) WO1998036755A1 (tr)
ZA (1) ZA981343B (tr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
PL337510A1 (en) * 1997-06-18 2000-08-28 Smithkline Beecham Plc Treatment of diabetes by means of derivatives of thiazolydinone and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
ATE300288T1 (de) * 1998-12-24 2005-08-15 Metabasis Therapeutics Inc Zusammensetzung enthaltend insulin- sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
DE60035163T2 (de) * 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
ES2218338T3 (es) * 2000-04-13 2004-11-16 Pfizer Products Inc. Efecto sinergico de gliburida y milrinona.
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CN100544717C (zh) 2002-09-20 2009-09-30 华生制药公司 含有双胍和噻唑烷二酮衍生物的药物剂型
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
RU2359661C2 (ru) 2003-10-31 2009-06-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
EP1943274A2 (en) * 2005-09-08 2008-07-16 Uutech Limited Treatment of diabetes related obesity
AU2006289259A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
NZ569071A (en) 2005-12-22 2011-01-28 Takeda Pharmaceutical Solid preparation containing an insulin sensitizer
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
PL2868315T3 (pl) 2007-12-04 2018-06-29 Biogen Chesapeake Llc Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
CA2745206C (en) * 2008-12-04 2018-09-18 Chongxi Yu High penetration compositions and their applications
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
JP5697260B2 (ja) * 2009-11-13 2015-04-08 東レ株式会社 糖尿病の治療または予防薬
WO2011146981A1 (en) 2010-05-24 2011-12-01 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
RU2620357C2 (ru) 2011-01-19 2017-05-24 Фрэктил Лэборэторис Инк. Устройство и способ обработки тканей
EP2782586A4 (en) * 2011-11-23 2015-07-01 Ozstar Therapeutics Pty Ltd ENHANCED SYNERGIC ANTIDIABETIC COMPOSITIONS
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
KR102245697B1 (ko) 2012-02-27 2021-04-28 프랙틸 래브러토리스 인코포레이티드 조직의 치료를 위한 열 절제 시스템，장치 및 방법
WO2013159066A1 (en) 2012-04-19 2013-10-24 Fractyl Laboratories, Inc. Tissue expansion devices, system and methods
EP3714826A1 (en) 2012-07-30 2020-09-30 Fractyl Laboratories, Inc. Electrical energy ablation systems and devices for the treatment of tissue
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
EP2903626A4 (en) 2012-10-05 2016-10-19 Fractyl Lab Inc METHODS, SYSTEMS AND DEVICES FOR CARRYING OUT MULTIPLE TREATMENTS OF A PATIENT
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
US11986235B2 (en) 2013-09-12 2024-05-21 Fractyl Health, Inc. Systems, methods and devices for treatment of target tissue
KR102284469B1 (ko) 2013-11-22 2021-08-02 프랙틸 헬쓰, 인코포레이티드 위장관에 치료 제한부를 생성하기 위한 시스템, 장치 및 방법
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
WO2016011269A1 (en) * 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
AU2015335603B2 (en) 2014-10-24 2020-04-30 Bristol-Myers Squibb Company Modified FGF-21 polypeptides and uses thereof
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2021102423A1 (en) * 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
AU741215B2 (en) 2001-11-29
AR011829A1 (es) 2000-09-13
HUP0001528A3 (en) 2000-12-28
IS5058A (is) 1999-05-27
US5859037A (en) 1999-01-12
HN1997000167A (es) 1999-02-09
ZA981343B (en) 1998-11-16
EE9900345A (et) 2000-02-15
AU5590898A (en) 1998-09-09
SV1998000010A (es) 1999-02-02
NO993982D0 (no) 1999-08-18
BR9714505A (pt) 2000-03-21
PE74399A1 (es) 1999-08-20
PA8447401A1 (es) 2001-12-14
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
IL130027A0 (en) 2000-02-29
CZ289299A3 (cs) 1999-11-17
NZ336002A (en) 2002-03-28
BG103671A (en) 2000-04-28
KR20000071179A (ko) 2000-11-25
PL335166A1 (en) 2000-04-10
CA2272478A1 (en) 1998-08-27
US5972973A (en) 1999-10-26
JP2001512478A (ja) 2001-08-21
NO993982L (no) 1999-08-18
EA199900725A1 (ru) 2000-04-24
IL130027A (en) 2005-09-25
WO1998036755A1 (en) 1998-08-27
EP0957923A1 (en) 1999-11-24
SK111899A3 (en) 2000-09-12
CN1244801A (zh) 2000-02-16
UY24893A1 (es) 1998-07-10

Similar Documents

Publication Publication Date Title
TR199902033T2 (tr) Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari.
DE69827001D1 (de) Gewebedezellularization
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
ATE324119T1 (de) Verwendung von saccharid-konjugaten
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
TR200101174T2 (tr) Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.
DE69012124D1 (de) Verbesserungen bei der behandlung von zähnen.
EA199800667A1 (ru) Новые фенантридины
ES2059121T3 (es) Uso de agentes sensibilizantes de insulina para tratar la hipertension.
ES2184800T3 (es) Uso de agentes anti-vegf en el tratamiento de la endometriosis.
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
TR200000662T2 (tr) Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi.
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
BR9808221A (pt) Método de tratamento de tumor.
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
TR200000135T2 (tr) Tiazolidinedion ve sülfonilüre ile diabet tedavisi.
BR9915214A (pt) Combinações contendo um beta-agonista e umagente anti-diabético adicional
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
NZ514691A (en) Method to type prion proteins
NO970607D0 (no) Anordning av selegilin i behandling av epileptiske tilstander
ATE200026T1 (de) Behandlung von laminitis
ZA981558B (en) Inclusion complexes in aqueous solution
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.